Warning added to Victrelis not to mix with HIV protease inhibitors
This article was originally published in Scrip
Executive Summary
The labelling for Merck's hepatitis C virus (HCV) medicine Victrelis (boceprevir) is being revised to warn about the potential for drug interactions with ritonavir-boosted HIV protease inhibitors, such as Bristol-Myers Squibb's Reyataz (atazanavir), Janssen Pharmaceuticals' Prezista (darunavir) and Abbott's Kaletra (lopinavir/ritonavir), US regulators said.